Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as GBX 9 ($0.12) and last traded at GBX 8.50 ($0.12), with a volume of 127774 shares trading hands. The stock had previously closed at GBX 8.50 ($0.12).
Allergy Therapeutics Stock Performance
The firm’s 50 day moving average is GBX 8.14 and its 200 day moving average is GBX 7.17. The company has a market cap of £405.15 million, a PE ratio of -1,180.56, a PEG ratio of -30.70 and a beta of 1.40. The company has a debt-to-equity ratio of 835.48, a current ratio of 1.63 and a quick ratio of 1.48.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Read More
- Five stocks we like better than Allergy Therapeutics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Loop Industries Insiders Buy Stock, Signal Confidence in Outlook
- What is Forex and How Does it Work?
- Joby Aviation’s Pullback: A Gift for Investors Who See the Future
- How to Start Investing in Real Estate
- Kohl’s Stock Rebound Faces a Showdown With Short Sellers
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
